STOCKHOLM--(BUSINESS WIRE)--The exercise period for warrants of series TO 2 (not listed) and warrants of series TO 4 (listed) closed on October 18th 2016. In total 3.237.816 warrants of both series were exercised, resulting in a utilization of over 98 percent. Through the warrants, Cantargia raises around MSEK 24.6, before issue costs.
Warrants of series TO 2 were issued in connection with a debt-for-equity swap in October 2014 and warrants of series TO 4 were issued in connection with the initial public offering in March 2015. In total, 394.688 warrants of series TO 2 and 2.843.128 warrants of series TO 4 were exercised, resulting in the registration of 3.237.816 new shares at the Swedish Companies Registration Office. Cantargia will thereby get approximately MSEK 24.6 before issue costs. The number of shares will after registration at the Swedish Companies Registration Office amount to 20.917.200 shares and the share capital will be SEK 1.673.376.
"We are obviously very pleased with the strong support that our shareholders have shown us during this subscription period," says Göran Forsberg, CEO. "The interest shown regarding the intensified investment in our programs, is most stimulating."
This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 24 October 2016, at 08.30.
This information was brought to you by Cision http://news.cision.com
If you have any questions concerning Cantargia’s warrants, please contact:
Telephone: +46 (0)40-615 14 10
Göran Forsberg, CEO
Telephone: 046-275 62 60
Certified Adviser: Sedermera Fondkommission
Last updated on: 25/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.